Cargando…
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect
Dabigatran, directly targeting thrombin, is widely used for the prevention of stroke in nonvalvular atrial fibrillation (NVAF). We reported a rare case of left atrial appendage thrombus formation in a persistent NVAF patient despite the 31 months uninterrupted treatment with dabigatran 110 mg twice...
Autores principales: | Gu, Zhi-Chun, Ma, Xiao-Wei, Zheng, Xiao-Yuan, Shen, Long, Shi, Fang-Hong, Li, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962821/ https://www.ncbi.nlm.nih.gov/pubmed/29867495 http://dx.doi.org/10.3389/fphar.2018.00491 |
Ejemplares similares
-
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report
por: Wu, Tingting, et al.
Publicado: (2020) -
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
por: Zhu, Zhu, et al.
Publicado: (2022) -
The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
por: Liu, Yue, et al.
Publicado: (2021) -
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016) -
Dabigatran for left atrial thrombus
por: Morita, Sae, et al.
Publicado: (2013)